Rising Drug Prices Demonstrate Need for Inflation Reduction Act’s Changes
This week marked the one-year anniversary of the signing of the Inflation Reduction Act (IRA), landmark legislation that allows Medicare
📢 Action Needed: Tell Congress to Protect Federal Funding
The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
This week marked the one-year anniversary of the signing of the Inflation Reduction Act (IRA), landmark legislation that allows Medicare
As we near the first anniversary of the Inflation Reduction Act (IRA), recent public polling by KFF shows that many
The Inflation Reduction Act (IRA) made key changes to improve prescription drug affordability for people with Medicare. Important reforms that
For many low-income Medicare beneficiaries, the Part D Low-Income Subsidy (LIS) program (also called “Extra Help”) can be a lifeline,
This week, the pharmaceutical giant Merck sued the U.S. Department of Health and Human Services (HHS), challenging Medicare’s authority to
A recently released study found that in 2022, over 20% of adults 65 and older experienced cost-related medication nonadherence, meaning
This week, the Centers for Medicare & Medicaid Services (CMS) finalized proposed policy changes to Medicare Advantage (MA) and Part
Callers to our national helpline regularly report struggling to afford the prescription medications they need to maintain their health and well-being. The Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program could offer much-needed relief. In our comments, we offer recommendations to implement this program in a way that enhances affordability, ensures accuracy, and maximizes transparency.
Implementation of the drug pricing provisions of the Inflation Reduction Act (IRA) is underway. This week, Medicare Rights submitted comments
The Inflation Reduction Act’s (IRA) Rebate Program will require drug companies to pay a rebate if they raise certain Part D drug prices faster than inflation, reining in the industry practice of sky-high annual price adjustments. This deterrent will strengthen beneficiary and program finances.
This week marked the one-year anniversary of the signing of the Inflation Reduction Act (IRA), landmark legislation that allows Medicare
As we near the first anniversary of the Inflation Reduction Act (IRA), recent public polling by KFF shows that many
The Inflation Reduction Act (IRA) made key changes to improve prescription drug affordability for people with Medicare. Important reforms that
For many low-income Medicare beneficiaries, the Part D Low-Income Subsidy (LIS) program (also called “Extra Help”) can be a lifeline,
This week, the pharmaceutical giant Merck sued the U.S. Department of Health and Human Services (HHS), challenging Medicare’s authority to
A recently released study found that in 2022, over 20% of adults 65 and older experienced cost-related medication nonadherence, meaning
This week, the Centers for Medicare & Medicaid Services (CMS) finalized proposed policy changes to Medicare Advantage (MA) and Part
Callers to our national helpline regularly report struggling to afford the prescription medications they need to maintain their health and well-being. The Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program could offer much-needed relief. In our comments, we offer recommendations to implement this program in a way that enhances affordability, ensures accuracy, and maximizes transparency.
Implementation of the drug pricing provisions of the Inflation Reduction Act (IRA) is underway. This week, Medicare Rights submitted comments
The Inflation Reduction Act’s (IRA) Rebate Program will require drug companies to pay a rebate if they raise certain Part D drug prices faster than inflation, reining in the industry practice of sky-high annual price adjustments. This deterrent will strengthen beneficiary and program finances.